Monogenic mutations affecting CTLA-4 or proteins in its pathway affect Treg function (8, 9) and antibodies that block activation of TGF-β by human Tregs prevent their ability to control xenogeneic graft-versus-host disease (GVHD) (10). Here, CTLA4 is linked to graft versus host disease.